StockStory.org on MSN
3 reasons OCUL is risky and 1 stock to buy instead
Over the last six months, Ocular Therapeutix’s shares have sunk to $10.44, producing a disappointing 7.4% loss - a stark ...
Patients with psoriasis are at increased risk for cataracts, uveitis, dry eye disease, glaucoma, retinal vein occlusion (RVO) ...
Chronic rhinosinusitis (CRS) significantly affects ophthalmologic health but remains largely manageable, according to a ...
Signs and symptoms of ocular surface disease could be significantly reduced within 4 days after treatment with shelf-stable ...
StockStory.org on MSN
Ocular Therapeutix (NASDAQ:OCUL) surprises with Q3 CY2025 sales
Ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) reported Q3 CY2025 results , but sales fell by 5.7% ...
Hemodialysis significantly alters anterior and posterior eye segments, affecting parameters like anterior chamber depth, lens ...
BOSTON, MA, UNITED STATES, January 8, 2026 /EINPresswire.com/ -- EyeCool Therapeutics, a clinical-stage ophthalmic ...
The Pooled Cohort Equations (PCE) cardiovascular risk score stratifies risk for multiple ocular diseases, according to a ...
Ocular motor apraxia (OMA) is a neurological condition resulting in an inability to turn the eyes voluntarily in a horizontal manner. Ocular Motor Apraxia is known by a variety of terms. OMA is ...
Aims This study aimed to explore ocular and systemic factors associated with pathologic myopia in patients with high myopia ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results